Rimonci Capital

TECLens, LLC is a development-stage company based in St. James, New York, focused on designing and manufacturing innovative medical contact lenses aimed at treating myopia and other vision issues. Founded in 2013, the company has developed the CXLens, a corneal crosslinking lens that offers a non-invasive, single treatment therapy requiring only a half-hour wear in a doctor's office. This technology features real-time ultrasound sensing and a high oxygen concentration environment for precise scleral positioning, enhancing targeting stability during treatment. TECLens aims to address a range of vision problems, including progressive myopia in children, presbyopia in adults, and conditions such as keratoconus. By providing a comfortable and effective alternative to traditional corrective lenses, TECLens seeks to reduce long-term eye health risks associated with extensive lens use.

Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

EyeYon Medical is an Israeli startup based in Jerusalem, developing innovative medical devices focused on treating corneal edema. The company's flagship product, Hyper-CL, is a hyperosmotic contact lens designed to extract fluids from the cornea through osmosis, improving vision and relieving pain. Additionally, EyeYon Medical has developed DSPEK, an artificial endothelial layer intended to replace injured tissue that can cause corneal edema. Founded by Dr. Daphna Ofer, Dr. Arie Marcovich, and Nahum Ferera, the company operates within the Van Leer Technology Incubator.

EyeControl is a medical technology company that develops innovative communication solutions for individuals with severe speech impairments, such as those affected by locked-in syndrome or ALS. Their flagship product is an intuitive glass frame equipped with an infrared camera, which translates eye movements into spoken commands via a connected computer and earphones/speaker. This device aims to enhance patients' quality of life by facilitating easier communication and improving access to healthcare services.

BELKIN Vision is a company focused on developing innovative laser devices to aid healthcare professionals in the treatment of glaucoma. Its products are characterized by being non-invasive, non-contact, instantaneous, painless, and automated, providing effective laser therapy options. The company's mission is to enhance accessibility to first-line drop-less glaucoma care, enabling any ophthalmologist to effectively treat patients. By streamlining the treatment process, BELKIN Vision aims to improve patient outcomes and overall quality of care within the medical community.

NovaSight Ltd, founded in 2016 and based in Israel, is dedicated to advancing pediatric vision care through innovative technology. The company has developed CureSight, an eye-tracking system specifically designed for the treatment of amblyopia in children. This integrated, AI-driven solution allows for precise vision assessments and streamlined treatments, catering to the unique needs and attention spans of young patients. NovaSight aims to prevent vision impairments among children by incorporating data analytics into its medical devices, facilitating novel diagnostic, therapeutic, and preventive approaches in pediatric ophthalmology. The company’s management and advisory board includes seasoned professionals and experts in pediatric vision care, underscoring its commitment to improving eye care for children.

6over6 is a digital healthcare company that has developed a platform allowing users to conduct their own eye vision tests using their smartphones. By integrating essential optometric tools into a mobile application, the company enables users to obtain accurate measurements of refractive errors, which are necessary for eyeglasses and contact lens prescriptions. Their product, GlassesOn, is registered as a Class 1 Exempt Medical Device with the FDA, emphasizing the company's commitment to safety and regulatory compliance. While GlassesOn facilitates effective vision assessment, it does not offer medical advice and is not a substitute for a comprehensive eye health examination. Through this innovative approach, 6over6 aims to enhance accessibility to vision care for a broader audience.

BELKIN Vision is a company focused on developing innovative laser devices to aid healthcare professionals in the treatment of glaucoma. Its products are characterized by being non-invasive, non-contact, instantaneous, painless, and automated, providing effective laser therapy options. The company's mission is to enhance accessibility to first-line drop-less glaucoma care, enabling any ophthalmologist to effectively treat patients. By streamlining the treatment process, BELKIN Vision aims to improve patient outcomes and overall quality of care within the medical community.

EyeYon Medical is an Israeli startup based in Jerusalem, developing innovative medical devices focused on treating corneal edema. The company's flagship product, Hyper-CL, is a hyperosmotic contact lens designed to extract fluids from the cornea through osmosis, improving vision and relieving pain. Additionally, EyeYon Medical has developed DSPEK, an artificial endothelial layer intended to replace injured tissue that can cause corneal edema. Founded by Dr. Daphna Ofer, Dr. Arie Marcovich, and Nahum Ferera, the company operates within the Van Leer Technology Incubator.